The Mammotome Revolve™ Dual Vacuum–Assisted Breast Biopsy System Has Evolved
September 26, 2024
CINCINNATI, OHIO – September 26, 2024 – Mammotome is thrilled to unveil enhancements to the Mammotome Revolve™ biopsy system, a device that is a cornerstone in procedural efficiency and tissue quality in the breast care suite. The newly refined system represents the most substantial upgrades to the device to date, focused on improving ease of use for clinicians and their staff. 1,2
The Mammotome Revolve™ biopsy system is engineered for accuracy, repeatability and efficiency, while staying true to its purpose of acquiring the best quality tissue during the patient’s ultrasound or stereotactic biopsy. 3,4 The evolution of the Mammotome Revolve™ biopsy system includes several key enhancements to the user experience. The control module, user interface and cart have all been elevated to optimize efficiency and ease of use.1 These enhancements ensure that clinicians can perform biopsy procedures with greater simplicity and fewer steps. Additionally, the upgraded cart provides additional workspace while maintaining a minimal footprint in the biopsy suite. During early customer feedback sessions, all 15 out of 15 Radiologists surveyed agreed that the newly refined Mammotome Revolve™ system saves them time in their stereotactic or ultrasound procedures.
The newly refined system retains its original standout features, including an advanced tissue management system that automatically collects and organizes specimens in touch-free chambers, simplifying tissue verification. Also, the user-controlled variable aperture allows for instant adjustments, enabling confident access to challenging lesions without the need to change the probe during the procedure.
“The launch of the newly refined Mammotome Revolve™ system2 marks an exciting milestone for Mammotome,” said Suzanne Smith, Vice President of America Sales, Global Service and Commercial Marketing. “These enhancements will empower clinicians to perform biopsy procedures with greater simplicity and efficiency. This advancement underscores our unwavering commitment to innovation and excellence in patient care.”
The launch in North America and Europe is underway and this product will be widely available this fall. In addition to North America and Europe, Mammotome anticipates that the newly refined Mammotome Revolve™ biopsy system will be available to clinicians in select countries across the globe by early 2025.
To learn more about the newly refined Mammotome Revolve™ biopsy system, click here.
Media Contact: Erica Bednar, Director of Marketing Communications
Phone: 513-391-4737
[email protected]
About Mammotome
At Mammotome, our expertise and compassion for breast care makes us the indispensable partner to physicians, clinicians and patients. Our drive for innovation is rivaled only by our compassion for the people we serve, from the clinicians and surgeons who demand consistently precise solutions, to the patients and families seeking peace of mind. We boast a comprehensive range of products that create better outcomes in breast care and provide physicians and patients with educational resources that guide their journey. Headquartered in Cincinnati, OH, Mammotome has been part of the Danaher Corporation since 2014. The Mammotome brand of products is sold in over 45 different countries throughout the world.
###
1. Mammotome Revolve™ Device Tests: PCR-000794 -Summative Usability, PCR-000523 - Design Validation, ES-002810 - Claims Assessment, ES-002811- IFU Comparison Investigation
2. System refinements include simple and intuitive user interface, upgraded cart with tray that enables additional workspace with minimal footprint, and increased efficiency and ease of use for clinicians and staff.
3. Evaluation of two different vacuum-assisted breast biopsy systems: Mammotome® system 11G/8G vs. ATEC® system 12G/9G
4. Ozerdem, U. (n.d.). Adequate core biopsy samples from stereotactic biopsies needed for today’s breast pathology.
© 2024 Devicor Medical Products, Inc. All rights reserved. Devicor, Mammotome, and Mammotome Revolve are registered trademarks of Devicor Medical Products, Inc., in the USA and optionally in other countries. Other logos, product and/or company names might be trademarks of their respective owners. MDM# 240625 Rev 9/24